Show simple item record

dc.contributor.authorAbu Eid, Rasha
dc.contributor.authorWard, Frank James
dc.date.accessioned2022-09-22T23:17:11Z
dc.date.available2022-09-22T23:17:11Z
dc.date.issued2021-12
dc.identifier.citationAbu Eid , R & Ward , F J 2021 , ' Targeting the PI3K/Akt/mTOR pathway : A therapeutic strategy in COVID-19 patients   ' , Immunology Letters , vol. 240 , pp. 1-8 . https://doi.org/10.1016/j.imlet.2021.09.005en
dc.identifier.issn0165-2478
dc.identifier.otherPURE: 200423798
dc.identifier.otherPURE UUID: bf2b5a0c-bd26-45d8-b22f-7ca66aff1daf
dc.identifier.otherScopus: 85115975872
dc.identifier.urihttps://hdl.handle.net/2164/19216
dc.descriptionFunding This work was supported by Friends of ANCHOR pilot research award [grant number RS 2019 004, 2020-2021]en
dc.format.extent8
dc.language.isoeng
dc.relation.ispartofImmunology Lettersen
dc.rightsThis manuscript version is made available under the CC-BY-NC-ND 4.0 license https://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.subjectCOVID-19en
dc.subjectPI3Ken
dc.subjectAkten
dc.subjectmTORen
dc.subjectImmune modulationen
dc.subjectThrombosisen
dc.subjectRK Dentistryen
dc.subjectOtheren
dc.subjectRS 2019 004en
dc.subject2020-2021en
dc.subject.lccRKen
dc.titleTargeting the PI3K/Akt/mTOR pathway : A therapeutic strategy in COVID-19 patients  en
dc.typeJournal itemen
dc.contributor.institutionUniversity of Aberdeen.Dental Educationen
dc.contributor.institutionUniversity of Aberdeen.Institute of Medical Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Medical Sciencesen
dc.description.statusPeer revieweden
dc.description.versionPostprinten
dc.identifier.doihttps://doi.org/10.1016/j.imlet.2021.09.005
dc.date.embargoedUntil2022-09-23


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record